We believe the healthcare system can be better — more accessible to more people — and we are part of the solution. Access is ingrained in every part of our business, from our portfolio that prioritizes greater patient options for access and affordability, to our commitment as public health advocates, collaborating with government agencies, trade associations, coalitions and nonprofit organizations.
The Amneal Accessibility Index is a multidimensional model for understanding and communicating what “access” really means in the U.S. pharmaceutical system — reframing accessibility not as a price issue, but as a systemic outcome shaped by affordability, availability, support, innovation, and policy.
How much medicines cost, driven by manufacturing costs, intermediary costs, payor coverage and benefit design, and financial support programs.
How readily medicine can be procured, driven by manufacturing capacity, quality and redundancy, supply chain resilience, formulation, flexibility and geographic distribution coverage.
The understanding of conditions and their treatments by providers, patients and the general public.
Advancements that improve outcomes and quality of life, driven by novel therapeutics and molecule discovery, drug format/administration enhancements, and better care delivery models.
We’ve always prioritized access in our portfolio, and we continue to do so in our pipeline. In 2024, we launched 22 new retail generics and expanded our biosimilars work— providing lower-cost alternatives for important biologics. We also added five more biosimilars to our pipeline with launches slated for 2026–2027. In Specialty, we launched two new products in under 2 years. We continue to focus on innovations that address unmet need and our commitment to expanded access, because we believe innovation means nothing if people can’t access it.
Timeline(Opens in a new window) Pipeline(Opens in a new window)
Our patient assistance program is just one of the many ways we help patients in need. Since 2012, our patient assistance program has provided free or discounted medicines to thousands of eligible patients.
Save on Unithroid®
10,000+
U.S. Specialty & Biosciences patient support programs assisted 10,000+ patients in 2025
CREXONT® Patient
Assistance Program
Our U.S. generic copay
card helped patients
save on their out of
pocket costs 7,077
times in 2025
Corporate
India